A blood test might predict who will respond to Wegovy; Viridian’s thyroid eye disease drug wins another Phase 3; Ideaya drops two GSK-returned assets. 🧬

BASEL, Switzerland — Pharma manufacturing in Switzerland appears to be unperturbed by the threat of tariffs, but it might take several years before the impact

Pfizer has discontinued the final clinical study stemming from its 2021 acquisition of Trillium Therapeutics, funneling cash primarily toward a host of other cancer and

Johnson & Johnson will move a treatment for inflammatory bowel disease into Phase 3 studies despite the therapy’s failure in two mid-stage trials. The company

Cytokinetics’ Myqorzo has succeeded where BMS’s first-to-market Camzyos failed, with a positive trial in non-obstructive hypertrophic cardiomyopathy.